Latest Breaking News On - Harrington discovery institute at university hospitals - Page 7 : comparemela.com

Date Time Share Case Western Reserve and Atelerix Life Sciences Inc. sign option license to develop new therapeutic approach to opioid crisis Novel small molecule technology reverses life-threatening opioid-induced respiratory depression without diminishing pain relief Case Western Reserve University and Atelerix Life Sciences Inc., a Charlottesville, Virginia-based biotechnology company, have signed a two-year option to license a novel family of small molecules called Active Thiol-Based Compounds (ATBC’s) to prevent or reverse life-threatening opioid-related side effects. The lead compound, ATLX-0199 (also called sudaxine), will be first targeted at opioid-induced respiratory depression (OIRD) in the hospital setting. A recent study by the medical technology company Medtronic found that 46% of surgical patients receiving opioids for post-operative pain-relief suffer one or more episodes of OIRD, presenting perhaps the most significant obstacle to discharge from intensive ca

United statesJames batesDavid kalergisBenjamin gastonStephen lewisStephanie weidenbecherCase western reserve school of medicineHarrington discovery institute at university hospitalsAtelerix life sciencesNational institutes of healthBlood institute catalyze programUniversity of iowa carver college medicineCase western reserve technology transfer officeDepartment of pediatricsCase western reserve universityAtelerix life sciences inc